Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/7/2024 | $323.00 → $536.00 | Hold → Buy | Jefferies |
| 6/16/2023 | $390.00 → $405.00 | Neutral → Buy | BofA Securities |
| 4/11/2023 | $330.00 → $400.00 | Equal-Weight → Overweight | Stephens |
| 12/14/2022 | $250.00 | Hold | Deutsche Bank |
| 11/30/2022 | $250.00 | Neutral | UBS |
| 10/28/2022 | $385.00 → $250.00 | Buy → Neutral | BofA Securities |
| 7/30/2021 | $350.00 → $475.00 | Overweight | Keybanc |
10-Q - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
S-8 POS - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
EXTON, Pa., Oct. 29, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following conferences: UBS Global Healthcare Conference in Rancho Pablos Verdes, California, on November 12, 2024 at 3:30 PM PSTJefferies Healthcare Conference in London, UK on Tuesday, November 19, 2024 at 1:00 PM GMTStephens Annual Investment Conference in Nashville, TN on Thursday, November 21, 2024 at 10:00 AM CSTA live audio webcast of these events will be available
- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., Oct. 24, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the third-quarter 2024 and declared a fourth-quarter 2024 dividend. Third-Quarter 2024 Summary (comparisons to prior-year period) Net sales of $746.9 million declined 0.1%; organic net sales decline was 0.5%.Reported-diluted EPS of $1.85, compared to $2.14 in the same period last year.Adjusted-diluted EPS of $1.85, compared to $2.16 in the same period last year.As a result of favorable currency move
EXTON, Pa., Oct. 22, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced participation in the 2024 PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Phoenix, AZ to showcase its leadership and expertise on industry challenges and trends in packaging and containment. "With the rise of biologic drugs, injectables are the fastest growing drug segment today, bringing with it new challenges of complex molecules and treatment requirements," says Atul Pate
The Company is updating full-year 2024 net sales guidance to a range of $2.870 billion to $2.900 billion, compared to a prior range of $3.000 billion to $3.025 billion. Organic net sales are now expected decrease approximately 1% to 2%. Net sales guidance includes an estimated full-year 2024 headwind of approximately $5.0 million based on current foreign currency exchange rates, compared to prior guidance of approximately $8.0 million. Full-year 2024 adjusted-diluted EPS is expected to be in a range of $6.35 to $6.65, compared to prior guidance range of $7.63 to $7.88. Full-year adjusted-diluted EPS guidance range includes an estimated headwind of approximately $0.03 based o
CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal
EXTON, Pa., May 12, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today the appointment of West's Chief Financial Officer (CFO) Bernard J. Birkett to a newly combined position of Chief Financial and Operations Officer. In this expanded role, Mr. Birkett will lead our Global Operations and Global Supply Chain. The Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo has announced his resignation to pursue other interests with a departure of July 2022 to ensure a seamless transition.
4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)
SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)
SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)
- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., Oct. 24, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the third-quarter 2024 and declared a fourth-quarter 2024 dividend. Third-Quarter 2024 Summary (comparisons to prior-year period) Net sales of $746.9 million declined 0.1%; organic net sales decline was 0.5%.Reported-diluted EPS of $1.85, compared to $2.14 in the same period last year.Adjusted-diluted EPS of $1.85, compared to $2.16 in the same period last year.As a result of favorable currency move
EXTON, Pa., Oct. 10, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter financial results before the market opens on Thursday, October 24, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast will be made available via the Company's Investor Relations website click here. To ask questions on the conference call, participants need to register in advance
- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., July 25, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the second-quarter 2024 and updated full-year 2024 financial guidance. Second-Quarter 2024 Summary (comparisons to prior-year period) Net sales of $702.1 million declined 6.9%; organic net sales declined 5.9%.Reported-diluted EPS of $1.51, compared to $2.06 in the same period last year.Adjusted-diluted EPS of $1.52, compared to $2.11 in the same period last year. The Company is updating full-year 20
Jefferies upgraded West Pharm from Hold to Buy and set a new price target of $536.00 from $323.00 previously
BofA Securities upgraded West Pharm from Neutral to Buy and set a new price target of $405.00 from $390.00 previously
Stephens upgraded West Pharm from Equal-Weight to Overweight and set a new price target of $400.00 from $330.00 previously